You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease
SBC: Oleolive, Inc. Topic: NIASUMMARY Alzheimer’s disease (AD) and related dementias are devastating conditions that affect millions of people, but no effective treatment options exist. Studies are currently being performed as part of the funded Phase II STTR parent award to test efficacy of a potential AD therapeutic, OL-003, in two additional animal models and assess pharmacology and toxicology. The overarching goal of the ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Early and accurate diagnosis of pulmonary and extrapulmonary tuberculosis in all patient groups using a circulating pathogen-derived antigen
SBC: Nanopin Technologies, Inc. Topic: NIAIDPROJECT SUMMARYNanoPin is advancing a diagnostic for active tuberculosis (TB) that addresses critical unmet clinical needs and its innovation and potential patient impact has resulted in designation as a breakthrough device by the FDA. This device will highly valuable in the global effort to combat TB, which is now the leading cause of death from infectious disease, with an estimated 10.0 million ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Peptide inhbitors of influenza entry-FAST TRACK
SBC: Autoimmune Technologies, LLC Topic: NIAIDDESCRIPTION (provided by applicant): Between 10% and 20% of the United State population suffer from seasonal influenza each year. While most individuals recover from influenza in one to two weeks, the very young, the elderly and persons with chronic medical conditions can develop post-flu pneumonia and other lethal complications. The causative agent of influenza is influenza virus, a myxovirus tha ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
A-007: Immune Modulation of HPV- Associated Neoplasia
SBC: DEKK-TEC INC Topic: N/ADESCRIPTION (provided by applicant): 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) was originally developed as an immune modulator of immune deficiency associated cancerous growths. In a recent study, A-007 was administered as a topical gel to treat anogenital cancers associated with the human papillomavirus (HPV). There were no local or systemic toxicities and excellent responses ...
SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health -
Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing
SBC: AXOSIM, INC. Topic: NCATSPROJECT SUMMARY The drug development pipeline is plagued by unacceptable rates of attrition due in large part to toxicities that are not identified in pre clinical stages of developmentThe ability to de risk lead compounds during pre clinical development with advancedorganoid on a chiptechnologies shows tremendous promiseDrug induced neurotoxicity is caused by off target effects of pharmaceuticals ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive biomarkers for gastrointestinal disease in preterm infants
SBC: CHOSEN DIAGNOSTICS INC Topic: NICHDPROJECT SUMMARY Our objective is to develop a clinically-usable test that can diagnose gastrointestinal disease early in infants. Initially described nearly 200 years ago, necrotizing enterocolitis (NEC) is the most frequent gastrointestinal disorder in preterm infants. It affects 7-12% of preterm infants born with very low birth weight (lt 1.5 kg). Thus, nearly 6,000 preterm infants per year suff ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
IND-Enabling Studies of ZB716, an Orally Bioavailable SERD
SBC: Zenopharm, LLC Topic: 102Project Summary Fulvestrant is the only FDA approved selective estrogen receptor downregulatorSERDindicated for advanced metastatic breast cancer that has progressed after or during tamoxifen or aromatase inhibitorAItreatmentIn July and Augustfulvestrant was approved as a first line endocrine agent for breast cancer patients by the European Medicines AgencyEMAand US FDArespectivelyHoweverthe drug ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel non-narcotic analgesic for acute and chronic pain
SBC: South Rampart Pharma, LLC Topic: 104Abstract Acute and chronic pain affect more than 50 million Americans and there is an enormous unmet need for safer pain relief. Although acetaminophen (ApAP) is among the medicines most commonly used for pain relief, hepatotoxicity is a risk and overdose is the most common cause of acute fulminant hepatic failure. Oxidation of ApAP to N-acetyl-p-benzoquinone imine (NAPQI) leads to hepatotoxicity. ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Peptide inhbitors of influenza entry-FAST TRACK
SBC: Autoimmune Technologies, LLC Topic: N/ADESCRIPTION (provided by applicant): Between 10% and 20% of the United State population suffer from seasonal influenza each year. While most individuals recover from influenza in one to two weeks, the very young, the elderly and persons with chronic medical conditions can develop post-flu pneumonia and other lethal complications. The causative agent of influenza is influenza virus, a myxovirus tha ...
SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
Adipose Derived Stromal Stem Cell Therapy for Pressure Ulcers
SBC: LaCell LLC Topic: NIADESCRIPTION provided by applicant This Phase II SBIR extends a Phase I proof of principle study originally submitted in response to RFA AG entitled andquot T Translational Research on Agingandquot from the NIA In Phase I LaCell has documented pre clinical safety and efficacy of a novel adipose derived cell therapy for the treatment of pressure ulcers in young and old mice The inject ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health